75.09

6.67% 4.98

10 X Genomics Inc (TXG)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$70.11

Offen:

$70.13

24-Stunden-Volumen:

1.55M

Relative Volume:

0.50

Marktkapitalisierung:

$9.77B

Einnahmen:

$638.78M

Nettoeinkommen (Verlust:

$-22.66M

KGV:

-430.56

EPS:

-0.1744

Netto-Cashflow:

$122.18M

1W Leistung:

+14.00%

1M Leistung:

+33.33%

6M Leistung:

+298.01%

1J Leistung:

+460.19%

1-Tages-Spanne:

$70.11

$75.61

1-Wochen-Bereich:

$63.50

$75.61

52-Wochen-Spanne:

$11.16

$75.61

10 X Genomics Inc Stock (TXG) Company Profile

Firmenname

10 X Genomics Inc

Sektor

Healthcare (1073)

Branche

Health Information Services (46)

Telefon

(925) 401-7300

Adresse

6230 STONERIDGE MALL ROAD, PLEASANTON, CA

Mitarbeiter

1,178

Twitter

@10xgenomics

Nächster Verdiensttermin

2026-11-05

Neueste SEC-Einreichungen

TXG's Discussions on Twitter

Compare TXG vs VEEV, TEM, BTSG, HQY

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
TXG 10 X Genomics Inc	75.02	8.94B	638.78M	-22.66M	122.18M	-0.1744
VEEV Veeva Systems Inc	271.31	42.48B	3.32B	941.65M	1.64B	5.6161
TEM Tempus Ai Inc	66.37	10.71B	1.36B	-302.91M	-219.93M	-1.7182
BTSG Brightspring Health Services Inc	58.54	11.62B	13.65B	169.86M	412.12M	1.0758
HQY Healthequity Inc	96.62	7.96B	1.34B	230.70M	440.96M	2.6695

10 X Genomics Inc Stock (TXG) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-03-31	Hochstufung	William Blair	Mkt Perform → Outperform
2025-12-11	Herabstufung	Citigroup	Buy → Neutral
2025-12-02	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2025-09-11	Eingeleitet	Piper Sandler	Neutral
2025-02-13	Herabstufung	Leerink Partners	Outperform → Market Perform
2024-09-03	Eingeleitet	Leerink Partners	Outperform
2024-07-22	Hochstufung	Jefferies	Hold → Buy
2024-07-18	Herabstufung	JP Morgan	Overweight → Neutral
2024-07-10	Herabstufung	Deutsche Bank	Buy → Hold
2024-06-27	Herabstufung	Wolfe Research	Outperform → Peer Perform
2024-06-25	Herabstufung	Guggenheim	Buy → Neutral
2024-06-03	Fortgesetzt	Jefferies	Hold
2024-05-01	Herabstufung	TD Cowen	Buy → Hold
2023-12-14	Eingeleitet	Guggenheim	Buy
2023-12-13	Eingeleitet	Wolfe Research	Outperform
2023-12-12	Hochstufung	BofA Securities	Underperform → Neutral
2023-07-05	Fortgesetzt	JP Morgan	Overweight
2023-05-10	Eingeleitet	Barclays	Overweight
2023-03-31	Eingeleitet	Stephens	Overweight
2023-02-02	Eingeleitet	UBS	Neutral
2022-12-14	Eingeleitet	Deutsche Bank	Buy
2022-08-18	Herabstufung	Goldman	Neutral → Sell
2022-07-25	Eingeleitet	Canaccord Genuity	Buy
2022-07-15	Herabstufung	BofA Securities	Neutral → Underperform
2022-07-15	Herabstufung	William Blair	Outperform → Mkt Perform
2021-10-15	Fortgesetzt	Cowen	Outperform
2021-09-14	Herabstufung	BofA Securities	Buy → Neutral
2021-03-15	Eingeleitet	William Blair	Outperform
2020-12-02	Eingeleitet	Goldman	Neutral
2020-09-09	Eingeleitet	Morgan Stanley	Overweight
2020-07-10	Eingeleitet	Stifel	Buy
2020-03-05	Eingeleitet	Guggenheim	Buy
2020-01-07	Eingeleitet	Citigroup	Buy
2019-10-07	Eingeleitet	BofA/Merrill	Buy
2019-10-07	Eingeleitet	Cowen	Outperform
2019-10-07	Eingeleitet	JP Morgan	Overweight
2019-09-24	Eingeleitet	Evercore ISI	Outperform

Alle ansehen

10 X Genomics Inc Aktie (TXG) Neueste Nachrichten

Sep 12, 2026

Korea's Lunit announces collaboration with 10x Genomics for AI-enabled pathology analysis of cancer - BioSpectrum Asia

Sep 12, 2026

Moderna, 10x Genomics, Oscar Health, and Novavax Shares Are Soaring, What You Need To Know - Yahoo Finance

Sep 12, 2026

Sep 11, 2026

10x Genomics (TXG) CFO Adam Taich Sells 46,388 Shares - GuruFocus

Sep 11, 2026

10x genomics CFO Adam Taich disposes of $2.99 million in company stock - Investing.com Nigeria

Sep 11, 2026